Bristol-myers Squibb Compnay

Five Prime Therapeutics, Inc.

Ekaterina G Deyanova

Guodong Chen

Alan J Korman

Richard Y Huang

Mark J Selby

Paul O Sheppard

Michelle Minhua Han

Christine Bee

Xiao Min Schebye

Hong-An Truong

Brigitte Devaux

Huiming Li

Daniel F Ardourel

Andy X Deng

Anan Chuntharapai

Michelle Renee Kuhne

Andrew Rankin

Lin Hui Su

Xiaodi Deng

Richard Yu-Cheng Huang

Nils Lonberg

Arvind Rajpal

Ginger Chao Rakestraw

Aaron Paul Yamniuk

Linda Liang

Keith Sadoon Bahjat

Scott Ronald Brodeur

Achal Mukundrao Pashine

Robert J Johnston

Luis Borges

Stephen Michael Carl

Joseph Toth

Jason Robert Pinckney

Diana Yuhui Chen

David A Critton

Yun Wang

Alfred Robert Langish

Hong Shen

Haichun Huang

Mohan Srinivasan

Shrikant Deshpande

Akbar Nayeem

Li-Sheng Lu

Michael Quigley

Jun Zhang

Hadia Lemar

Hong-An Troung

Michelle Kuhne

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Antibodies binding to ILT4

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Antibodies against TIM3 and uses thereof

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Antibodies binding to vista at acidic pH

Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.

This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.

Anti-CD27 antibodies and uses thereof

Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7Rα). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.

Antibodies against IL-7R alpha subunit and uses thereof

Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R&#x3b1;). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.

Growing community of inventors

Lawrenceville, NJ, United States of America

Ekaterina G Deyanova